Medical Condition News

RSS

USPTO grants composition-of-matter patent to Zalicus 'Synavive' product

Zalicus Inc. announced today that it has been granted a composition-of-matter patent by the U.S. Patent and Trademark office covering its product candidate Synavive.

30 Mar 2011

BIOTRONIK completes patient enrollment in IN-TIME clinical trial to treat HF

BIOTRONIK SE & Co. KG, a leading manufacturer of cardiac devices, announced today that the last chronic heart failure patient was enrolled in IN-TIME at the Schwabing Clinic in Munich, Germany, with principle investigator Professor Stefan Sack, MD.

30 Mar 2011

Smoking withdrawal after liver transplantation may protect against neoplasia development

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies than patients who keep smoking.

30 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

Engineers create new microfluidic device that can detect cancer cells, HIV

A Harvard bioengineer and an MIT aeronautical engineer have created a new device that can detect single cancer cells in a blood sample, potentially allowing doctors to quickly determine whether cancer has spread from its original site.

30 Mar 2011

Researchers develop new drug for multiple cancer treatment

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.

30 Mar 2011

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Commission has granted marketing authorisation for Trobalt as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

30 Mar 2011

SHMT1 gene and folate deficiency increase risk for colon cancer

Offering a likely insight into how such cancers develop in humans - Cornell University researchers report they have identified a gene that increases the risk for colon cancer in laboratory mice when the animals' diets are deficient in folate.

30 Mar 2011

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.

30 Mar 2011

Study: Gene combinations may increase risk of hip osteoporosis in women

Women with osteoporosis in their hip suffer menopause two years earlier than healthy women, a study conducted at the University of Granada says. Additionally, although further study is required, researchers have found at least three genetic markers associated with osteoporosis in the hip in postmenopausal women.

30 Mar 2011

Transgenomic discovers novel BLOCker-Sequencing technology

Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.

30 Mar 2011

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Metabolic Solutions Development Company, a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.

30 Mar 2011

Osseon launches Osseoflex BT Steerable Bone Tamp for physicians

Osseon Therapeutics announced today at the Society of Interventional Radiology's Annual Meeting the launch of the Osseoflex BT Steerable Bone Tamp.

30 Mar 2011

Oral antioxidant formulation before medical imaging may minimize cell damage

A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

Study: Thyroid hormone deficiency can affect cone opsins and colour vision

Thyroid hormone controls the eye's visual pigments throughout life. What part does the thyroid gland have in vision? Thyroid hormone is crucially involved in controlling which visual pigment is produced in the cones. Previously, it was assumed that the colour sensitivity of the cones is fixed in the adult retina.

30 Mar 2011

Australian researchers say the search must widen for genes that cause heart defects in babies

Australian scientists have discovered a new group of genes that could be responsible for causing heart defects in children, which affect more than 2000 babies born each year in Australia.

29 Mar 2011

Eating disorders tough to conquer

Young people and adolescents have been repeatedly warned regarding eating disorders. Lisa Harmon Mollicone, coordinator of the Manalapan-Englishtown Community Alliance for the Prevention of Alcohol and Drug Abuse, addressed the topic of eating disorders at a full house during the Dec. 14 meeting of the alliance, held at the Manalapan Senior Center.

29 Mar 2011

Natural disasters can produce major lung problems

A comprehensive new review published in the journal Respirology indicates that lung problems are major causes of morbidity and mortality following natural disasters.

29 Mar 2011

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development.

29 Mar 2011

Medical expert says PSTD cases may increase following Japanese tsunami

The Japanese tsunami took quite a massive toll, injuring and killing thousands and causing billions of dollars in destruction. But looking beyond physical destruction, the tsunami took an emotional toll on many as well.

29 Mar 2011